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With respect to the use of time-weighted average HbA 1c levels, we used several different approaches for assessing HbA 1c levels including baseline values and time-dependent covariates. Each gave similar findings to those presented. The averaging method published was required by reviewers and deemed most understandable by clinicians.
With respect to potential treatment effects, we regard the randomised comparisons between the intensive and the standard glucose control groups, reported in our main results paper of 2008, to be the paramount result [3] . This takes account of the achieved difference in HbA 1c of 0.67% on average, and 0.7% at the end of the study, as well as differences in treatments. Since all models in our more recent paper adjusted for assignment to the intensive or standard glucose control treatment strategies [2] , it was deemed unnecessary and excessive also to adjust for use of therapeutic classes, including sulfonylureas and insulins, which were more commonly used in the intensive glucose control group. This approach was also followed by the ACCORD trial investigators in similar post hoc epidemiological analyses [4] . Furthermore, we avoided further post-randomisation adjustment since we believed this would introduce bias by indication.
Although unexpected, our finding of a difference in the magnitude of the association between HbA 1c and major outcomes by randomised treatment group was also reported by the ACCORD investigators [4] . Using updated average HbA 1c levels, ACCORD reported higher adjusted all-cause mortality risks for each 1% higher HbA 1c in the intensive compared with standard glucose treatment arms (intensive HR 1.66 [95% CI 1.46, 1.49] vs standard HR 1.14 [95% CI 0.95, 1.38]) [4] .
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